Belite Bio (Belite Bio) Equity-to-Asset : 0.95 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Belite Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $96.47 Mil. Belite Bio's Total Assets for the quarter that ended in Mar. 2024 was $101.15 Mil.

The historical rank and industry rank for Belite Bio's Equity-to-Asset or its related term are showing as below:

BLTE' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82 Med: 0.92 Max: 0.97
Current: 0.95

During the past 4 years, the highest Equity to Asset Ratio of Belite Bio was 0.97. The lowest was -0.82. And the median was 0.92.

BLTE's Equity-to-Asset is ranked better than
94.68% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs BLTE: 0.95

Belite Bio Equity-to-Asset Historical Data

The historical data trend for Belite Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Equity-to-Asset Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-0.27

-0.82

0.94

0.96

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial							0.88	0.92	0.92	0.96	0.95

Competitive Comparison of Belite Bio's Equity-to-Asset

For the Biotechnology subindustry, Belite Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Belite Bio's Equity-to-Asset falls into.

Belite Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Belite Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	90.431	/	94.642
	=

Belite Bio's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	96.47	/	101.147
	=

Belite Bio (NAS:BLTE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Belite Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Belite Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.